Ocuphire Pharma Results Presentation Deck

Broad Opportunities to Treat Retinal Diseases with APX Platform APX3330 May Treat Patients Across Retinal Diseases as Single Agent or Adjunctive Therapy Addressable Market Mild NPDR 6M US Market Opportunity 34 Million Diabetics in US 10M Diabetic Retinopathy Moderate to Severe NPDR (DRSS 43-53) 1M ~8M+ DR Patients ~$10B+ Market Revenues PDR (DRSS >60) 1M APX3330 APX3330 APX2009/APX2014/APX3330 (Local Delivery) + Anti-VEGF treatments Inflammatory component is common across these retina indications as well & potentially addressable by MOA of Ref-1 DME 1M Source: 1. American Diabetes Association; International Diabetes Federation; Healthline; *Ocuphire internal analysis and assumptions; 2. Das UN. DME, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci. 2016;12(5):1142-1157. doi:10.5114/aoms.2016.61918 3. Patient survey adapted from Lions International Foundation and International Diabetes Foundation-Europe; Meltzer 2000 4. Estimates are provided by the National Eye Institute, FactSheet, Global Data, and Research and Markets. Estimated values are rounded. 26 5. Estimated prevalence in the U.S.; DME- Diabetic Macular Edema; Age-related Macular Degeneration; Geographic Atrophy; Retinal Vein Occlusion Wet AMD 2M Dry AMD 10M+ GA 1M Potential First Oral Rx for Retina Diseases with Multi-Billion Revenue Opportunity Ocuphire

View entire presentation